Early studies suggest that cosibelimab’s dual functionality—engaging both the adaptive immune system via PD-1/PD-L1 blockade and the innate immune system via ADCC—could result in more robust and sustained anti-tumor responses, particularly in challenging cases where other therapies might fail [65]. The gene discussed is PDCD1; the disease is neoplasm.